Loading...
Market
Will the combination therapy of nivolumab and ipilimumab be adopted as the standard of care for advanced melanoma by major cancer centers in the US by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements from major cancer centers and medical guidelines
Story
CheckMate 067: Decade of Immunotherapy Advances Boosts Advanced Melanoma Survival to 72 Months
Sep 16, 2024, 12:30 PM
A decade of advancements in immunotherapy has significantly improved survival rates for patients with advanced melanoma. The CheckMate 067 trial revealed that the combination of nivolumab and ipilimumab resulted in a median overall survival of 72 months, compared to 37 months with nivolumab alone and 20 months with ipilimumab alone. The trial results were presented at the European Society for Medical Oncology (ESMO) 2024 conference. Merck presented 10-year follow-up data for their immunotherapy, highlighting the long-term benefits in metastatic melanoma survival. The medical community, including Weill Cornell, acknowledges the progress but emphasizes that further work is needed. The double drug treatment raises survival rate for half of advanced melanoma to 10 years.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Tecentriq Hybreza gains the most market share • 25%
Keytruda gains the most market share • 25%
Opdivo gains the most market share • 25%
Other treatment gains the most market share • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
